Vor Biopharma Inc
vorbio.comWhat Do They Do?
Develops telitacicept, a fusion-protein treatment for autoimmune diseases including myasthenia gravis and Sjögren’s disease.
10-K for FY2025, filed Mar 30, 2026Vor Biopharma, Inc. ("Vor Bio") is a clinical-stage biopharmaceutical company focused on developing a novel therapy in the treatment of…View ↗
Telitacicept is approved in China for the treatment of systemic lupus erythematosus (“SLE”), rheumatoid arthritis (“RA”), and generalized…View ↗
Telitacicept is a novel fusion protein for treating autoimmune diseases. It is constructed with the extracellular domain of the human…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$62.8MView ↗
- ▼ −96% (Loss)
- vs −$1.6B in Q2 FY2025
-
Jun 8, 2026
RemeGen received China approvals for telitacicept in IgAN and Sjögren’s disease
The IgAN approval is conditional; RemeGen handles development, regulatory approvals and commercialization in China.
Sources
8-K, filed Jun 8, 2026
On June 8, 2026, Vor Biopharma Inc. (the “Company”) announced that RemeGen Co., Ltd. received conditional approval from the National…View ↗
A shift in therapeutic focus
The business has moved from engineering stem-cell transplants and pairing them with targeted therapies for blood cancers to developing telitacicept for autoimmune diseases.
10-K for FY2022, filed Mar 23, 2023Vor Bio’s proprietary platform aims to change the traditional target tumor approach by genetically engineering healthy cells by removing…View ↗
Leveraging our expertise in HSC biology and genome engineering, we genetically modify HSCs to remove surface targets and then provide these…View ↗
We intend to pair future eHSC product candidates with targeted therapeutics such as our VCAR33 programs, chimeric antigen receptor…View ↗
Loading...
